Cargando…

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

SARS-CoV-2 variants of concern (VOC) acquired mutations in the spike (S) protein, including E484K, that confer resistance to neutralizing antibodies. However, it is incompletely understood how these mutations impact viral entry into host cells. Here, we analyzed how mutations at position 484 that ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Markus, Sidarovich, Anzhalika, Arora, Prerna, Krüger, Nadine, Nehlmeier, Inga, Kempf, Amy, Graichen, Luise, Winkler, Martin S., Niemeyer, Daniela, Goffinet, Christine, Drosten, Christian, Schulz, Sebastian, Jäck, Hans-Martin, Pöhlmann, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239067/ https://www.ncbi.nlm.nih.gov/pubmed/35467423 http://dx.doi.org/10.1128/mbio.00364-22

Ejemplares similares

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein
por: Arora, Prerna, et al.
Publicado: (2022)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
por: Hoffmann, Markus, et al.
Publicado: (2022)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
por: Hoffmann, Markus, et al.
Publicado: (2021)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins
por: Plegge, Teresa, et al.
Publicado: (2019)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein
por: Budhadev, Darshita, et al.
Publicado: (2023)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
por: Wrensch, Florian, et al.
Publicado: (2017)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Hoffmann, Markus, et al.
Publicado: (2020)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Environmental Isolation of Candida auris from the Coastal Wetlands of Andaman Islands, India
por: Arora, Parth, et al.
Publicado: (2021)

Homologs of the Acinetobacter baumannii AceI Transporter Represent a New Family of Bacterial Multidrug Efflux Systems
por: Hassan, Karl A., et al.
Publicado: (2015)

Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication
por: Adams, Lily E., et al.
Publicado: (2021)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus
por: Kleine-Weber, Hannah, et al.
Publicado: (2020)

Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier
por: Lorin, Valérie, et al.
Publicado: (2020)

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2
por: Busnadiego, Idoia, et al.
Publicado: (2020)

Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses
por: Nascimento Conde, Jonas, et al.
Publicado: (2020)

Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71
por: Zhu, Ling, et al.
Publicado: (2018)

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
por: Zeng, Cong, et al.
Publicado: (2021)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Gallichotte, Emily N., et al.
Publicado: (2019)

The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells
por: Brinkmann, Constantin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4nr4nvt012lujk9nqq2ofod4bg